Originally published as JCO Early Release 10.1200/JCO.2005.03.6491 on May 8 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ramlau, R. Articles by Shepherd, F. A. Search for Related Content PubMed PubMed Citation Articles by Ramlau, R. Articles by Shepherd, F. A. Social Bookmarking                            What's this?

Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer

Rodryg Ramlau, Radj Gervais, Maciej Krzakowski, Joachim von Pawel, Eckhard Kaukel, Raymond P. Abratt, Bernie Dharan, Kelly M. Grotzinger, Graham Ross, Graham Dane, Frances A. Shepherd

From the Regional Lung Disease Centre, Oncology Department, Poznan; Centre of Oncology & Institute, Warsaw, Poland; Centre Francois Baclesse, Caen, France; Asklepios Klinik, Gauting bei Muenchen, Munich; Thoraxzentrum, Hamburg, Germany; University of Cape Town, Cape Town, South Africa; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Harlow, United Kingdom; and Princess Margaret Hospital, Toronto, Ontario, Canada

Address reprint requests to Rodryg Ramlau, MD, PhD, Lung Disease Centre, Oncology Department, ul.Szamarzewskiego 62, 60-569 Poznan, Poland; e-mail: rramlau{at}wcchpig.pl

PURPOSE: This open-label, randomized, multicenter, phase III study compared oral topotecan versus intravenous (IV) docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: Patients with stage III or IV NSCLC, performance status 2, who had received only one prior chemotherapy regimen, were randomly assigned to treatment with oral topotecan 2.3 mg/m²/d on days 1 to 5 or IV docetaxel 75 mg/m² day 1 every 21 days.

RESULTS: A total of 829 patients were randomly assigned. In intent-to-treat analysis, 1-year survival rates were 25.1% with topotecan and 28.7% with docetaxel. The difference of –3.6% (95% CI, –9.59% to 2.48%) met the predefined criteria for noninferiority of topotecan relative to docetaxel because the lower limit of the 95% CI was above –10%. Median survival was 27.9 weeks with topotecan and 30.7 weeks with docetaxel. Although not statistically significant (log-rank P = .057), the higher survival rate with docetaxel was maintained across the entire treatment period. The median time to progression was 11.3 weeks with topotecan versus 13.1 weeks with docetaxel (log-rank P = .02). The overall response rate was 5% in each group. Grade 3/4 neutropenia occurred more frequently with docetaxel (60% v 50%). Grade 3/4 anemia and thrombocytopenia occurred more frequently with topotecan (26% v 10% and 26% v 7%, respectively).

CONCLUSION: Oral topotecan provides activity in the treatment of relapsed, locally advanced, unresectable NSCLC. Both regimens were well tolerated with differing safety profiles. Topotecan may provide an option for patients who desire an orally available treatment after relapse.

Supported by GlaxoSmithKline, Middlesex, United Kingdom.

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Tassinari, L. Lazzari-Agli, P. Tombesi, and S. Sartori I Am No One. No One Is Perfect...Therefore I Am Perfect J. Clin. Oncol., October 1, 2009; 27(28): e128 - e129. [Full Text] [PDF]

				Y. Ichinose, M. Fukuoka, J.-Y. Douillard, M. Sellers, A. Armour, and E. Kim Reply to D. Tassinari et al J. Clin. Oncol., October 1, 2009; 27(28): e130 - e131. [Full Text] [PDF]

				D. Tassinari, E. Scarpi, S. Sartori, E. Tamburini, C. Santelmo, P. Tombesi, and L. Lazzari-Agli Second-Line Treatments in Non-small Cell Lung Cancer: A Systematic Review of Literature and Metaanalysis of Randomized Clinical Trials Chest, June 1, 2009; 135(6): 1596 - 1609. [Abstract] [Full Text] [PDF]

				N. Hawkins, D. A. Scott, and B. Woods How Far Do You Go? Efficient Searching for Indirect Evidence Med Decis Making, May 1, 2009; 29(3): 273 - 281. [Abstract] [PDF]

				J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]

				M. H. Cullen, P. Zatloukal, S. Sorenson, S. Novello, J. R. Fischer, A. A. Joy, M. Zereu, P. Peterson, C. M. Visseren-Grul, and N. Iscoe A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer Ann. Onc., May 1, 2008; 19(5): 939 - 945. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Oncologist, January 1, 2008; 13(suppl_1): 28 - 36. [Abstract] [Full Text] [PDF]

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				D. R. Gandara and A. M. Davies Oral Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer: The Bottom Line J. Clin. Oncol., June 20, 2006; 24(18): 2700 - 2701. [Full Text] [PDF]